Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx Inc (NASDAQ: ARDX) is a biopharmaceutical company pioneering first-in-class therapies for renal and gastrointestinal disorders. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Discover official press releases covering tenapanor developments, hyperphosphatemia research breakthroughs, and international collaboration updates with partners in Japan and China. Our curated collection includes financial results, manufacturing announcements, and expert analyses of ARDX's novel drug discovery platform.
Key content categories include FDA regulatory updates, phase 3 clinical trial results, partnership expansions, and financial performance reports. All materials maintain strict compliance with financial disclosure regulations while presenting complex medical information in accessible language.
Bookmark this page for real-time updates on ARDX's progress in developing treatments for chronic kidney disease and IBS-C. Regularly refreshed content ensures you stay informed about this innovative biotech leader's contributions to renal care and gastrointestinal health.
The IBS in America 2024 survey revealed that higher IBS-C symptom severity correlates with increased financial hardship. The analysis used FACIT-COST® and PROMIS® scales to assess financial toxicity and symptoms.
Safety data from the Phase 3 R-ALLY study in pediatric patients (12-18 years) with IBS-C showed no serious adverse events, with diarrhea being the only drug-related side effect. Additionally, a Phase 1 study demonstrated that tenapanor was not detectable in breast milk of healthy lactating females after repeated administration.
Ardelyx has strengthened its board of directors with the appointment of Merdad Parsey, M.D., Ph.D., a veteran biotech leader with over 25 years of pharmaceutical industry experience. Parsey, who recently retired as Chief Medical Officer at Gilead Sciences in 2025, brings extensive expertise in clinical development and leadership.
His impressive career includes key positions at prominent organizations:
- Chief Medical Officer at Gilead Sciences (2019-2025)
- Senior Vice President of early clinical development at Genentech (2015-2019)
- CEO of 3-V Biosciences (2010-2015)
Parsey's appointment aligns with Ardelyx's mission to develop first-in-class medicines for unmet medical needs. His background in research, early development, and clinical strategy positions him to support the company's growth objectives, including expanding their commercial products and building a robust medicine pipeline.
Ardelyx (Nasdaq: ARDX) has announced the acceptance of three abstracts for poster presentations at the Digestive Disease Week Conference (DDW) in San Diego, May 3-6, 2025. The presentations will showcase data on IBSRELA® (tenapanor), their FDA-approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults.
The three poster presentations will cover:
- Safety and tolerability of tenapanor in pediatric IBS-C patients
- A pharmacokinetic study of tenapanor in breast milk of healthy lactating females
- Correlation between IBS-C symptom severity and financial burden from the IBS in America 2024 survey
Additionally, Ardelyx will sponsor a Product Theater on May 4, featuring Dr. Satish Rao and Christina Hanson, NP, discussing clinical considerations for managing adult IBS-C patients, including efficacy and safety data from Phase 3 trials.
Ardelyx (NASDAQ: ARDX) has scheduled its first quarter 2025 financial results conference call for Thursday, May 1, 2025, at 4:30 p.m. Eastern Time. The biopharmaceutical company will discuss Q1 2025 financial performance and provide a business update during the call.
Investors can participate by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international). A live audio webcast will be available on the Investors section of Ardelyx's website at www.ardelyx.com, with a 30-day replay period following the call.
Ardelyx (NASDAQ: ARDX) announced a post-hoc analysis presentation of the OPTIMIZE Study for XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings in Boston. The study analyzed 330 patients with chronic kidney disease on dialysis with hyperphosphatemia.
XPHOZAH, the first FDA-approved phosphate absorption inhibitor (PAI), is designed to reduce serum phosphorus in adult CKD patients on dialysis as add-on therapy. The analysis revealed that among 40% of patients reporting diarrhea, those using loperamide had lower discontinuation rates (9.7%) compared to non-users (24.6%).
The company is also hosting an Exhibitor Showcase on April 11, 2025, focusing on hyperphosphatemia management, where Dr. Vincent Carsillo will discuss XPHOZAH's mechanism of action, efficacy, and safety data from Phase 3 trials.
Ardelyx (NASDAQ: ARDX) announced that a post-hoc analysis of their OPTIMIZE Study for XPHOZAH® (tenapanor) will be presented at the National Kidney Foundation Spring Clinical Meetings in April 2025. The study involved 330 patients with chronic kidney disease on dialysis with hyperphosphatemia.
XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is FDA-approved to reduce serum phosphorus in adult CKD patients on dialysis as an add-on therapy. It's specifically indicated for patients with inadequate response to phosphate binders or those intolerant to binder therapy. The medication is administered as a single tablet twice daily.
The poster presentation will focus on how tenapanor-treated patients using over-the-counter antidiarrheal agents experienced decreased stool frequency and improved stool consistency. Additionally, Ardelyx will sponsor an Exhibitor Showcase discussing hyperphosphatemia management strategies and XPHOZAH's clinical application.
Ardelyx (NASDAQ: ARDX) has announced the first recipients of the Derek Forfang Patient Advocate Award on World Kidney Day. The award, established in memory of Derek Forfang who passed away in 2023 due to chronic kidney disease (CKD) complications, recognizes outstanding leaders in CKD advocacy.
The inaugural recipients are Mary Baliker, Erich Ditschman, Nichole Jefferson, Curtis Warfield, and David M. White. Selected by Ardelyx's Derek Forfang Patient Advisory Council, these advocates were chosen for their significant contributions to the CKD community. The awardees will be honored at the upcoming National Kidney Foundation Spring Clinical Meetings.
Each recipient has demonstrated exceptional dedication to improving patient care, healthcare policies, and awareness of kidney disease challenges. Their work spans various areas including patient education, health equity advocacy, policy reform, and research advancement.
Ardelyx (ARDX) has received approval from China's Center for Drug Evaluation for tenapanor, a treatment to control serum phosphorus levels in dialysis patients with chronic kidney disease who have inadequate response or intolerance to phosphorus binders. The approval triggers a $5 million milestone payment from their Chinese partner Fosun Pharma.
Under the agreement, Ardelyx is eligible for additional milestones up to $100 million and tiered royalties of mid-teens to 20% on net sales. The drug will be marketed in China as 'Wan Ti Le'. The approval is particularly significant given that China has over one million maintenance hemodialysis patients, growing at 12% annually, with 76% experiencing hyperphosphatemia. Currently, only 39% of patients achieve target phosphate levels under China's hemodialysis standards.
Ardelyx (NASDAQ: ARDX) has announced its participation in three major healthcare investor conferences in March 2025. The company will present at the Leerink Partners 2025 Global Healthcare Conference on March 11 at 8:00 a.m. ET, attend the Jefferies Biotech on the Beach Summit on March 12, and participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on March 13 at 10:00 a.m. ET.
All events will take place in Miami, FL. Live webcasts of the Leerink presentation and Barclays fireside chat will be available on the Events and Presentations page of the Ardelyx website (ir.ardelyx.com), with replays accessible for 30 days following each event. The company will also conduct one-on-one meetings during all three conferences.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
